Definium Therapeutics says Phase 3 Voyage trial meets primary endpoint for DT120 ODT in generalized anxiety disorder
DFTX•Phase 3 Voyage trial meets primary endpoint
Definium Therapeutics reported positive topline results from its Phase 3 Voyage trial of DT120 ODT in generalized anxiety disorder.
The study met the primary endpoint, showing a clinically meaningful reduction in anxiety symptoms versus placebo.
Secondary measures improved and safety was favorable
Key secondary measures also improved, with benefits seen quickly and sustained through Week 12.
DT120 ODT was generally well tolerated, with no new safety signals reported.
Panorama Phase 3 GAD topline results are expected in September, following this readout and a prior positive Phase 3 result in depression.
